Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation

Fig. 6

Schematic illustration of the effects of tanimilast and budesonide on LPS-moDC phenotype and function. DCs matured in the presence of tanimilast express distinct phenotypical and functional properties when compared to budesonide, characterized by the upregulation of CD141 expression and the acquisition of Th2-skewing properties. Bold lettering indicates that the upregulation of IL-12p40, TSP1, VEGF-A, AREG and CD141 was also observed in vivo in sputum cells of COPD patients treated with tanimilast on top of standard-of-care therapy

Back to article page